Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis

Circulation

Volumn 108, Issue 3, 2003, Pages 270-274

  O'Brien, Kevin D ^a   Vuletic, Simona ^b   McDonald, Thomas O ^a   Wolfbauer, Gertrud ^b   Lewis, Katherine ^b   Tu, An Yue ^b   Marcovina, Santica ^b   Wight, Thomas N ^c   Chait, Alan ^b   Albers, John J ^b,d  

^a Division of Cardiology   (United States)

^b Division of Metabolism Endocrinology and Nutrition   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Northwest Research Laboratory   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; Cells; Lipids; Lipoproteins

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL; GLYCAN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; MESSENGER RNA; PHOSPHOLIPID TRANSFER PROTEIN; PROTEOGLYCAN; VERSICAN;

ARTICLE; ATHEROGENESIS; CELL CULTURE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; EXTRACELLULAR MATRIX; FOAM CELL; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBODY SPECIFICITY; APOLIPOPROTEINS; CARRIER PROTEINS; CELLS, CULTURED; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; EXTRACELLULAR MATRIX PROTEINS; EXTRACELLULAR SPACE; FOAM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS, HDL; MACROPHAGES; MEMBRANE PROTEINS; MUSCLE, SMOOTH, VASCULAR; PHOSPHOLIPID TRANSFER PROTEINS; PROTEOGLYCANS; RNA, MESSENGER;

EID: 0041807631     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000079163.97653.CD     Document Type: Article

References (32)

1. Jiang XC, Bruce C. Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. J Biol Chem. 1995;270:17133-17138.
2. Tall AR, Krumholz S, Olivecrona T, et al. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res. 1985;26:842-851.
3. Tu AY, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem. 1993;268:23098-23105.
4. Jauhiainen M, Metso J, Pahlman R, et al. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem. 1993;268:4032-4036.
5. Wolfbauer G, Albers JJ, Oram JF. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim Biophys Acta. 1999;1439:65-76.
6. Tollefson JH, Ravnik S, Albers JJ. Isolation and characterization of a phospholipid transfer protein (LTP-II) from human plasma. J Lipid Res. 1988;29:1593-1602.
7. Jiang XC, Bruce C, Mar J, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest. 1999;103:907-914.
8. Murdoch SJ, Carr MC, Hokanson JE, et al. PLTP activity in premenopausal women: relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J Lipid Res. 2000;41:237-244.
9. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
10. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
11. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
12. Jiang X, Francone OL, Bruce C, et al. Increased preβ-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest. 1996;98:2373-2380.
13. von Eckardstein A, Huang Y, Assmann G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol. 1994;5:404-416.
14. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
15. Jiang XC, Qin S, Qiao C, et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med. 2001;7:847-852.
16. O'Brien KD, Olin KL, Alpers CE, et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation. 1998;98:519-527.
17. Gordon D, Reidy MA, Benditt EP, et al. Cell proliferation in human coronary arteries. Prac Natl Acad Sci U S A. 1990;87:4600-4604.
18. Gown AM, Tsukada T, Ross R. Human atherosclerosis, II: immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol. 1986;125:191-207.
19. Skalli O, Ropraz P, Trzeciak A, et al. A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol. 1986;103:2787-2796.
20. Isogai Z, Shinomura T, Yamakawa N, et al. 2B1 antigen characteristically expressed on extracellular matrices of human malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cacer Res. 1996;56:3902-3908.
21. Murdoch SJ, Wollbauer G, Kennedy H, et al. Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. J Lipid Res. 2002;43:281-289.
22. Chait A, Henze K, Mazzone T, et al. Low density lipoprotein receptor activity in freshly isolated human blood monocytes and lymphocytes. Metabolism. 1982;31:721-727.
23. Albers JJ, Wollbauer G, Cheung MC, et al. Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies. Biochim Biophys Acta. 1995;1258:27-34.
24. Cheung MC, Wollbauer G, Albers JJ. Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. Biochim Biophys Acta. 1996;1303:103-110.
25. Hailman E, Albers JJ, Wollbauer G, et al. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J Biol Chem. 1996;271:12172-12178.
26. Schonherr E, Jarvelainen HT, Sandell LJ, et al. Effects of platelet-derived growth-factor and transforming growth factor-beta-1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth-muscle cells. J Biol Chem. 1991;266:17640-17647.
27. Camejo G, Fager G, Rosengren B, et al. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem. 1993;268:14131-14137.
28. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
29. Zhang Z, Yamashita S, Hirano K, et al. Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis. 2001;159:67-75.
30. Saxena U, Klein MG, Vanni TM, et al. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. J Clin Invest. 1992;89:373-380.
31. Olin KL, Potter-Perigo S, Barrett PH, et al. Biglycan, a vascular proteoglycan, binds differently to HDL2 and HDL3: role of apoE. Arterioscler Thromb Vasc Biol. 2001;21:129-135.
32. Karkkainen M, Oka T, Olkkonen VM, et al. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem. 2002;277:15413-15418.